Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ginkgo Bioworks Holdings (DNA)
NYSE:DNA
Ginkgo Bioworks Holdings (DNA) Stock Price & Analysis
1,898 Followers
DNA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.26 - $2.55
Previous Close$0.32
Volume68.87M
Average Volume (3M)56.06M
Market Cap
$714.69M
Enterprise Value-$7.55M
Total Cash (Recent Filing)$944.07M
Total Debt (Recent Filing)$221.84M
Price to Earnings (P/E)―
Beta2.68
Next Earnings
Aug 13, 2024EPS Estimate
-$0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding2,211,277,968
10 Day Avg. Volume37,152,099
30 Day Avg. Volume56,056,067
Standard Deviation0.22
R-Squared0.12
Alpha-0.08
Financial Highlights & Ratios
Price to Book (P/B)0.97
Price to Sales (P/S)2.88
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.03
Enterprise Value/Gross Profit-0.04
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$0.67Price Target Upside93.36% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering4
Ginkgo Bioworks Holdings News
PremiumCompany Announcements
Ginkgo Bioworks: Addressing NYSE Standards Noncompliance
Bulls Say, Bears Say
Bulls Say
AI In HealthcareThe AI panel discussion emphasized the potential for AI to enable quantitative biology and contribute to early disease detection, monitoring, and treatment.
Project VersatilityGinkgo highlighted a broad range of projects underway with many of its users, showing versatility in its genomic and automation capabilities.
Strategic CollaborationsGinkgo's expanded alliance with Novo Nordisk is expected to enhance manufacturing of therapeutics for chronic diseases, highlighting the company's growing collaborations.
Bears Say
Business ModelGinkgo no longer has conviction that its key 'cell program add' metric is highly correlated to revenue growth, making future revenue modeling difficult.
EarningsGinkgo delivered its third consecutive tough quarter, missing Q1 and lowering its 2024 revenue guidance.
Operational EfficiencyGinkgo announced a significant 25%+ headcount reduction and up to a 60% reduction in physical footprint.
---
Ownership Overview
8.72% Insiders
11.24% Mutual Funds
62.49% Other Institutional Investors
17.55% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DNA FAQ
What was Ginkgo Bioworks Holdings’s price range in the past 12 months?
Ginkgo Bioworks Holdings lowest stock price was $0.26 and its highest was $2.54 in the past 12 months.
What is Ginkgo Bioworks Holdings’s market cap?
Currently, no data Available
When is Ginkgo Bioworks Holdings’s upcoming earnings report date?
Ginkgo Bioworks Holdings’s upcoming earnings report date is Aug 13, 2024 which is in 42 days.
How were Ginkgo Bioworks Holdings’s earnings last quarter?
Ginkgo Bioworks Holdings released its earnings results on May 09, 2024. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.083 by $0.003.
Is Ginkgo Bioworks Holdings overvalued?
According to Wall Street analysts Ginkgo Bioworks Holdings’s price is currently Undervalued.
Does Ginkgo Bioworks Holdings pay dividends?
Ginkgo Bioworks Holdings does not currently pay dividends.
What is Ginkgo Bioworks Holdings’s EPS estimate?
Ginkgo Bioworks Holdings’s EPS estimate is -$0.08.
How many shares outstanding does Ginkgo Bioworks Holdings have?
Ginkgo Bioworks Holdings has 1,709,064,000 shares outstanding.
What happened to Ginkgo Bioworks Holdings’s price movement after its last earnings report?
Ginkgo Bioworks Holdings reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.083. Following the earnings report the stock price went down -17.391%.
Which hedge fund is a major shareholder of Ginkgo Bioworks Holdings?
Among the largest hedge funds holding Ginkgo Bioworks Holdings’s share is ARK Investment Management LLC. It holds Ginkgo Bioworks Holdings’s shares valued at 220M.
---
Ginkgo Bioworks Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$0.67 (93.36% Upside)
$0.67 (93.36% Upside)
Blogger Sentiment
Bullish
DNA Sentiment 72%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 14.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.63%
12-Months-Change
Fundamentals
Return on Equity
-65.81%
Trailing 12-Months
Asset Growth
-34.56%
Trailing 12-Months
Company Description
Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings (NYSE:DNA) is a biotechnology company that offers a platform for cell programming that enables the biological production of various products across the food, pharmaceutical, and fragrance industry. Its platform provides equipment, software, robotic automation, and tools to support genetic engineering, analytics, and fermentation.
---
DNA Company Deck
---
DNA Earnings Call
Q1 2024
0:00 / 0:00
---
DNA Revenue Breakdown
57.08% Cell Engineering
42.92% Biosecurity
---
DNA Stock 12 Month Forecast
Average Price Target
$0.67
▲(93.36% Upside)
Technical Analysis
Best Analysts Covering DNA
1 Year
1 Year Success Rate
2/14 ratings generated profit
1 Year Average Return
-25.79%
reiterated a sell rating 7 days ago
Copying Mark Massaro's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -25.79% per trade.
---